Current Studies

The facts about participating in clinical research and our ongoing studies:

First and foremost your safety is our top priority. Participating in clinical research gives you access to the latest medical and scientific innovations in medicine as well as compensates the participant(s) for time and travel. Most importantly, you are advancing medical science by contributing to the development of vital new medicines and paving the way for these new medicines to reach the market.

Please let us know if you are interested in participating in a research study. Study participants receive medical care, lab tests, and study medication at no cost, and are compensated for their participation. Transportation can be provided.

For more information, please call: 954-366-0277.



To participate or refer a patient, call 954-366-0277; Ext 120 – Jorge, Ext 121 – Rebecca, Ext 124 – Lucy.

Clinical Coordinators: Jorge Riveros, IMG, CCRC • Rebecca Nembhard, CCRC • Lucy Vargas, MA, CRC

T3D PIONEER: Mild to moderate Alzheimer’s Disease – A 28-week randomized study to evaluate the efficacy, safety and tolerability of an oral investigational medication vs. placebo in subjects with mild to moderate Alzheimer’s Disease, must have a study partner, ages 50-90. (MMSE 16-26)

Neuraly: Early Parkinson’s Disease – A 36-week randomized double-blind study to evaluate the efficacy, safety and tolerability of an oral medication vs. placebo in Early Parkinson’s Disease, ages 30-80.

Satsuma-Migraine: A Randomized, Double Blind, Parallel group, Placebo controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in Acute Treatment of Migraine.

Aeon-Cervical Dystonia: A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia. Followed by an open label extension for 1 year for those who complete the Double-Blind study.

Lilly-Trailblazer 2-AACI-Alzheimer’s Disease: A Phase 2, Multicenter, Randomized, Double-Blind Placebo-Controlled, Study to Evaluate the Safety, Efficacy and Tolerability of donanemab in participants with early symptomatic Alzheimer’s Disease. Study partner is required.


To participate or refer a patient Call 954-475-8171, ext 146 (Maria) or ext 138 (Adriana)

Clinical Coordinators: Maria Gonzalez, RMA, CCRC and Adriana Araujo, CRC

Acadia: Parkinson’s Disease 063 – A 16-week Open label study of the Effects of treatment with Pimavanserin on Activities of Daily Living in subjects with Parkinson’s Disease Psychosis, must have a study partner

Aptinyx: Parkinson’s Disease – A study to evaluate NYX-458 in subjects with Mild Cognitive Impairment associated with Parkinson’s Disease, must have a study partner and be between 50-80 years of age.

Takeda: Parkinson’s Disease-A Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral TAK-071 in Parkinson’s patients with Cognitive Impairment and an Elevated Risk of Falls for people 40-75 years of age.

Axsome-Alzheimer’s with Agitation: A Phase 3, 12-Week, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-Arm, Fixed-dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer’s Type


To participate or refer a patient –Call 954-475-8171 Ext 134 (Michele)

Clinical Coordinators: Michele Fistel, LPN, CCRC • Adriana Araujo,CCRC • Fanny Gully CRC

Novartis: EXCHANGE – Advancing Relapsing-Remitting MS – A 6 month open label study for a new oral medication for MS, patients wanting to switch from taking beta-interferons, glatiramer acetate, fingolimod, dimethyl fumarate, or teriflunomide (must have been on these medications for at least 3 months). Patients must have had a relapse in the last 12 months. Extension study to follow, for patients completing the 6-month study. Participants must be between 18-65 years old.

Sanofi- Gemini 2: Relapsing MS— (SPMS or RRMS) A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis (GEMINI 2). Participants must be 18-55 years old.

Novartis-Artios: –Relapsing MS— (SPMS or RRMS) A single-arm, prospective, open-label study to evaluate ofatumumab treatment effectiveness and patient reported outcomes in patients with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy. Participants must be 18-60 years old.

Novartis: OLIKOS--Relapsing MS (SPMS or RRMS) A 12 month, single-arm, multi-center study to explore maintained efficacy with ofatumumab therapy in patients with relapsing Multiple Sclerosis who discontinue intravenously delivered anti-CD20 monoclonal antibody (aCD2mAb) therapy (Ocrelizumab or Rituximab) Participants must be 18-55 years old.

Roche: GAROTTE–Primary Progressive MS (PPMS) Phase 3 A 2 year, multicenter, randomized, double blind controlled study to evaluate the efficacy and safety of a higher dose of Ocrelizumab in adults with Primary Progressive Multiple Sclerosis. With a 96 week open label extension for patients that complete the core study. Participants must be 18-55 years old.

Novartis-COMB157GUS16: An open-label multicenter study to assess response to COVID-19 vaccine in participants with multiple sclerosis treated with ofatumumab 20 mg subcutaneously